Funding profile · Genomic sample preparation

Volta Labs

Two Regulation D offerings on file total $37.7 million sold. The first was announced at a smaller number than it recorded. The second, closed over the winter of 2023 and 2024, was never announced at all.

$37.7MSold across Volta Labs Form D offerings, 2022 and 2024
$25.0MSold in the 2022 offering, 24 investors, fully subscribed
$12.7MSold in the 2023 to 2024 offering, no press release found
$1.45MRaised by an E14 single company vehicle from 10 investors

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Before 2022 Seed Not disclosed Maverick Ventures and other venture firms Independent
Jan 2022 first sale, announced Mar 17, 2022 Series A $20.0M announced; $25,034,971 offered and sold per Form D Maverick Ventures (lead), Khosla Ventures, Casdin Capital, E14 Funds, Blindspot Ventures, John Stuelpnagel, Anne Wojcicki, Paul McEwan Form D and release
Jan 2022 first sale, filed Apr 2023 E14 SPV Volta Labs A, LLC $1,450,777 10 investors; managed by E14 SPV GP, LLC Form D
Dec 2023 first sale, amended Mar 2024 Unnamed equity offering $12,681,692 sold of $20,000,001 offered 15 investors, not named Form D
2018 to 2026 Federal grants None found NIH and NSF searches return no awards Not found

What the filings show

Volta Labs, Inc. · Form D · filed Mar 3, 2022

First sale
Jan 27, 2022
Offered
$25,034,971 equity
Sold
$25,034,971 · $0 remaining
Investors
24 · average about $1,043,000
Exemption
Rule 506(b)
Related persons
Udayan Umapathi (executive officer, director, promoter); David Singer, Natan Linder, Maxim Lobovsky (directors); Will Langford (promoter)
Filing
SEC EDGAR, CIK 0001914755. Incorporated in Delaware, 2018. Address then Cambridge, MA

Volta Labs, Inc. · Form D/A · filed Mar 22, 2024

First sale
Dec 29, 2023
Offered
$20,000,001 equity, raised from $9,000,001 in the original Jan 12, 2024 notice
Sold
$12,681,692 · $7,318,309 remaining
Investors
15 · average about $845,000
Exemption
Rule 506(b)
Related persons
Udayan Umapathi (executive officer, director); David Singer, Natan Linder (directors)
Filing
SEC EDGAR, CIK 0001914755. Address Boston, MA

E14 SPV Volta Labs A, LLC · Form D · filed Apr 27, 2023

First sale
Jan 20, 2022
Type
Pooled investment fund, venture capital fund
Sold
$1,450,777 · offering size stated as indefinite
Investors
10 · average about $145,000
Exemptions
Rule 506(b); Investment Company Act 3(c)(1)
Related persons
E14 SPV GP, LLC (manager); Habib Haddad and Calvin Chin (managing members of the manager)
Filing
SEC EDGAR, CIK 0001972095. Signed Apr 26, 2023

Reading the filings

  1. The announced number is smaller than the filed number.The Series A was reported on March 17, 2022 as $20 million. The Form D filed two weeks earlier records $25,034,971 offered and the same amount sold, from 24 investors, first sale January 27, 2022. That averages about $1,043,000 each. GenomeWeb reported over $25 million raised in total including seed, so the filing appears to roll seed and Series A together.
  2. The filing was late, and still beat the press release.A Form D is due within 15 days of the first sale, so the January 27, 2022 sale made this one due about February 11. It was filed March 3, roughly three weeks late, and two weeks before the round was reported.
  3. The second round tripled in ten weeks and was never announced.The January 12, 2024 notice showed $9,000,001 offered and $4,260,001 sold to 4 investors. The March 22, 2024 amendment raised the offering to $20,000,001 and reported $12,681,692 sold to 15. That is $8,421,691 and 11 investors added in about ten weeks. No release naming a Series B was found. Callisto launched on February 1, 2024, between the two filings.
  4. Check size fell as the investor count rose.The 2022 round averaged about $1,043,000 per investor. The first four investors in the 2024 round averaged about $1,065,000. The 11 who followed averaged about $766,000 each. The offering also closed $7,318,309 short of its raised target.
  5. An MIT affiliated vehicle got in early and filed 15 months late.E14 SPV Volta Labs A, LLC reported $1,450,777 from 10 investors, about $145,000 each, with a first sale on January 20, 2022, one week before Volta’s own first sale. The notice was signed April 26, 2023. E14 Funds was named as a Series A participant.
  6. The board shrank on paper.The 2022 filing lists four directors plus a second promoter. Both 2024 filings list only Umapathi, David Singer and Natan Linder. Maxim Lobovsky and co-founder Will Langford no longer appear.
  7. Nothing has been filed for 30 months.A sweep of Form D notices by filers named Volta, running through July 2026, turns up nothing further under CIK 0001914755 after March 22, 2024. Companies raising under Section 4(a)(2) file no Form D, so silence is not proof that no money moved.

Commercial signals

Signal Detail Source type
Instrument price $125,000 list price reported at the February 2024 launch. Independent
First shipment Icahn School of Medicine at Mount Sinai, announced Sep 10, 2024. Instrument counts have never been disclosed. Company-stated
Named clinical users UMC Utrecht, Hartwig Medical Foundation, Norwegian Sequencing Centre at the University of Oslo. Company-stated
Third party data Broad Clinical Labs reported equivalent short read sensitivity and specificity against its own clinical genome workflow on 12 blood samples, Feb 2024. Independent
Regulatory Research Use Only. No FDA 510(k) or PMA. No registered trials. Public record
Revenue Not disclosed. Both Form D filings decline to state a revenue range. Not found

What to watch

  • A Form D for any financing after March 2024. It would be due 15 days after the first sale.
  • An amendment closing the $7,318,309 still unsold on the 2024 offering.
  • Whether a new director appears on a filing, which would mark a priced institutional round.
  • Any disclosed instrument count or revenue figure.

The Volta Labs story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Culture Biosciences: Shared investor: E14 Fund. A cloud lab that ran other companies’ fermentation for them, now selling the bioreactor itself through Cytiva
  • Medium Biosciences: Shared investor: E14 Fund. A small San Francisco company that says it designs custom affinity reagents with AI and delivers them in weeks
  • Science Exchange: Shared investor: Maverick Ventures. A marketplace for ordering experiments that became procurement software for big pharma, and that sourced the laboratories for the largest public test of whether
  • Nest Genomics: Shared investor: Casdin Capital. Software built to carry a genetic test result through a health system, from finding the patient to reminding the family years later

Sources

  1. Public recordForm D, Volta Labs, Inc., CIK 0001914755SEC · Mar 3, 2022
  2. Public recordForm D, Volta Labs, Inc.SEC · Jan 12, 2024
  3. Public recordForm D/A, Volta Labs, Inc.SEC · Mar 22, 2024
  4. Public recordForm D, E14 SPV Volta Labs A, LLC, CIK 0001972095SEC · Apr 27, 2023
  5. Public recordForm D sweep of filers named Volta, 2011 to July 2026SEC EDGAR
  6. IndependentVolta Labs Raises $20M in Series A Financing RoundGenomeWeb · Mar 17, 2022
  7. IndependentVolta Labs Launches Electrowetting-Based Automated NGS Sample Prep PlatformGenomeWeb · Feb 7, 2024
  8. CompanyVolta Labs Launches Callisto to Revolutionize Genomics and Sample PrepPR Newswire · Feb 1, 2024
  9. CompanyVolta Labs Announces First Customer ShipmentsPR Newswire · Sep 10, 2024

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Volta Labs. This page is not an offer to sell or a recommendation to buy any security.